Paricalcitol
Paricalcitol Basic information
- Product Name:
- Paricalcitol
- Synonyms:
-
- CS-1390
- PARICALCITOL (10 MG)F0E3030.997MG/MG(AI)
- PARICALCITOL
- 19-nor-1alpha,25-dihydroxyvitamin D2
- (1R,3R)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-6-Hydroxy-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol
- Zemplar
- 1,3-Cyclohexanediol, 5-[(2E)-2-[(1R,3aS,7aR)-octahydro-1-[(1R,2E,4S)-5-hydroxy-1,4,5-trimethyl-2-hexen-1-yl]-7a-methyl-4H-inden-4-ylidene]ethylidene]-, (1R,3R,5Z)-
- Paricalcitol, >=98%
- CAS:
- 131918-61-1
- MF:
- C27H44O3
- MW:
- 416.65
- EINECS:
- 658-064-6
- Product Categories:
-
- Vitamin D3 analogs
- Chiral Reagents
- Intermediates & Fine Chemicals
- Pharmaceuticals
- 131918-61-1
- Mol File:
- 131918-61-1.mol
Paricalcitol Chemical Properties
- Boiling point:
- 564.8±50.0 °C(Predicted)
- Density
- 1.121±0.06 g/cm3(Predicted)
- Flash point:
- 14℃
- storage temp.
- Store at -20°C,unstable in solution, ready to use.
- solubility
- DMSO : 100 mg/mL (240.02 mM; Need ultrasonic)Ethanol : 12.5 mg/mL (30.00 mM; Need ultrasonic)H2O : < 0.1 mg/mL (insoluble)
- pka
- 14.34±0.40(Predicted)
- form
- Solid
- color
- White to off-white
- InChIKey
- BPKAHTKRCLCHEA-UBFJEZKGSA-N
- SMILES
- C[C@]12CCC/C(=C\C=C3C[C@@H](O)C[C@H](O)C3)/[C@]1([H])CC[C@]2([H])[C@H](C)/C=C/[C@H](C)C(O)(C)C |&1:1,10,13,16,20,22,26,r|
- CAS DataBase Reference
- 131918-61-1(CAS DataBase Reference)
Safety Information
- RIDADR
- UN1170 - class 3 - PG 2 - Ethanol, solution
- HS Code
- 2936299055
- Hazardous Substances Data
- 131918-61-1(Hazardous Substances Data)
Paricalcitol Usage And Synthesis
Description
Paricalcitol was launched as Zemplar in the US for the prevention and treatment of secondary hyperthyroidism associated with chronic renal failure. Paricalcitol is a synthetic vitamin D2, namely a novel 1-alpha-hydroxy-19-noranalogue in which the ring A exocyclic methylene group, typical of all vitamin D systems, has been replaced by two hydrogen atoms. Paricalcitol is the first vitamin D analogue marketed for this indication. In patients with chronic renal failure, Paricalcitol appreciably reduced levels of parathyroid hormone (PTH) without a significant difference in the incidence rate for hypercalcemia or hyperphosphatemia when compared with placebo.
Description
Paricalcitol is a synthetic 1,25-dihydroxy vitamin D2 analog. As vitamin D deficiency, associated with chronic kidney disease, leads to an increase in parathyroid hormone (secondary hyperparathyroidism), paricalcitol is used in renal patients to block parathyroid hormone overproduction. Vitamin D deficiency is also a risk factor in cancer, cardiovascular disease, hypertension, and diabetes, and paricalcitol may have applications in those contexts as well.
Chemical Properties
White Solid
Originator
Abbott (US)
Uses
Antihyperparathyriod
Uses
1,25-Dihydroxy vitamin D2 is a potent agonist of the vitamin D receptor. Paricalcitol is a synthetic 1,25-dihydroxy vitamin D2 analog. As vitamin D deficiency, associated with chronic kidney disease, leads to an increase in parathyroid hormone (secondary hyperparathyroidism), paricalcitol is used in renal patients to block parathyroid hormone overproduction. Vitamin D deficiency is also a risk factor in cancer, cardiovascular disease, hypertension, and diabetes, and paricalcitol may have applications in those contexts as well.
Uses
Synthetic analog of vitamin D. Antihyperparathyroid.
Definition
ChEBI: Paricalcitol is a seco-cholestane and a hydroxy seco-steroid. It has a role as an antiparathyroid drug. It is functionally related to a vitamin D2.
brand name
Zemplar (Abbott).
Clinical Use
Vitamin D analogue:
Treatment and prevention of secondary
hyperparathyroidism associated with chronic renal
failure
Metabolism
Extensively metabolised via hepatic and non-hepatic
pathways to form two relatively inactive metabolites.
After oral administration of 3
H-paricalcitol, only about
2% of the dose was eliminated unchanged in the faeces,
and no parent drug found in the urine.
Approximately
70% of the radioactivity was eliminated in the faeces and
18% was recovered in the urine. Most of the systemic
exposure was from the parent drug.
ParicalcitolSupplier
- Tel
- 15011485209
- 17241816@qq.com
- Tel
- 021-50215258
- market@hypharma.com
- Tel
- 021-50790412
- info@chemvon.com
- Tel
- 027-02759101766 13125137661
- 2853877621@qq.com
- Tel
- sales@boylechem.com
Paricalcitol(131918-61-1)Related Product Information
- Matrine
- Zoledronic acid
- Argatroban
- 2-((3R,5R)-3,5-bis(tert-butyldiMethylsilyloxy)cyclohexylidene)ethanol
- (((1R,3R)-5-(2-chloroethylidene)cyclohexane-1,3-diyl)bis(oxy)) bis(tert-butyldimethylsilane)
- tert-butyl(((1R,3aR,7aR)-1-((2R,5S,E)-5,6-dimethyl -6-((tetrahydro-2H-pyran-2-yl)oxy)hept-3-en-2-yl) -7a-methyloctahydro-1H-inden-4-yl)oxy)dimethylsilane
- Calcium dobesilate
- Entacapone
- Emtricitabine
- Sofosbuvir
- Sevelamer hydrochloride
- (R)-(3-hydroxy-2,3-diMethylbutyl)triphenylphosphoniuM iodide
- Vitamin D2
- Calcifediol Monohydrate
- Secalciferol
- Paricalcitol Solution
- Paricalcitol
- 1(ALPHA) 25-DIHYDROXYVITAMIN D2*